JP2010538020A5 - - Google Patents

Download PDF

Info

Publication number
JP2010538020A5
JP2010538020A5 JP2010523239A JP2010523239A JP2010538020A5 JP 2010538020 A5 JP2010538020 A5 JP 2010538020A5 JP 2010523239 A JP2010523239 A JP 2010523239A JP 2010523239 A JP2010523239 A JP 2010523239A JP 2010538020 A5 JP2010538020 A5 JP 2010538020A5
Authority
JP
Japan
Prior art keywords
protein
crystallin
fragment
composition
angiogenic fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010523239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010538020A (ja
JP5685773B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2008/001319 external-priority patent/WO2009029991A1/en
Publication of JP2010538020A publication Critical patent/JP2010538020A/ja
Publication of JP2010538020A5 publication Critical patent/JP2010538020A5/ja
Application granted granted Critical
Publication of JP5685773B2 publication Critical patent/JP5685773B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010523239A 2007-09-07 2008-09-05 血管新生および創傷治癒活性がある薬剤 Expired - Fee Related JP5685773B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2007904857 2007-09-07
AU2007904857A AU2007904857A0 (en) 2007-09-07 Agents with angiogenic and wound healing activity
PCT/AU2008/001319 WO2009029991A1 (en) 2007-09-07 2008-09-05 Agents with angiogenic and wound healing activity

Publications (3)

Publication Number Publication Date
JP2010538020A JP2010538020A (ja) 2010-12-09
JP2010538020A5 true JP2010538020A5 (cg-RX-API-DMAC7.html) 2011-10-20
JP5685773B2 JP5685773B2 (ja) 2015-03-18

Family

ID=40428369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010523239A Expired - Fee Related JP5685773B2 (ja) 2007-09-07 2008-09-05 血管新生および創傷治癒活性がある薬剤

Country Status (6)

Country Link
US (1) US8404644B2 (cg-RX-API-DMAC7.html)
EP (2) EP2190455A4 (cg-RX-API-DMAC7.html)
JP (1) JP5685773B2 (cg-RX-API-DMAC7.html)
AU (1) AU2008295449A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ583803A (cg-RX-API-DMAC7.html)
WO (1) WO2009029991A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008295449A1 (en) * 2007-09-07 2009-03-12 Industrial Research Limited Agents with angiogenic and wound healing activity
EP2512492A1 (en) * 2009-12-14 2012-10-24 University of Massachusetts Methods of inhibiting cataracts and presbyopia
EP2668956A4 (en) * 2011-01-26 2015-11-11 Megmilk Snow Brand Co Ltd MEANS FOR IMPROVED SENSUAL ASSESSMENT
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
JP2014005254A (ja) * 2012-06-26 2014-01-16 Bfsr:Kk 熱傷由来全身性炎症反応症候群の予防外用薬
ES2727293T3 (es) 2013-03-14 2019-10-15 Univ Massachusetts Métodos de inhibición de cataratas y presbicia
KR20170040648A (ko) * 2015-10-05 2017-04-13 차의과학대학교 산학협력단 당뇨병성 족부궤양의 예방 또는 치료용 약학 조성물
CN108348494A (zh) 2015-11-13 2018-07-31 马萨诸塞大学 用于抑制白内障和老花眼的含peg的双官能分子
JP2022522247A (ja) * 2019-02-08 2022-04-14 オークランド ユニサービシズ リミテッド 生体材料およびそれに関連する方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187482A1 (en) * 1995-10-13 1997-04-14 Eri Inoue Pharmaceutical composition
WO1999051634A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-3
WO1999051738A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-4
JP2002527544A (ja) 1998-10-15 2002-08-27 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー フルオロシクロブチル環を含むポリマー及びその製造
JP3783200B2 (ja) * 2000-08-24 2006-06-07 株式会社加美乃素本舗 血管新生剤
US7263214B2 (en) 2002-05-15 2007-08-28 Ge Medical Systems Global Technology Company Llc Computer aided diagnosis from multiple energy images
AU2003234613A1 (en) 2002-05-15 2003-12-02 Seul, Kyung, Hwan Method of modulating angiogenesis
AU2003281325A1 (en) * 2002-07-02 2004-01-23 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
JPWO2004096277A1 (ja) * 2003-05-01 2006-07-13 国立大学法人京都大学 眼内血管新生疾患の予防又は治療剤
EP1624886A2 (en) * 2003-05-12 2006-02-15 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
US7456151B2 (en) * 2004-07-14 2008-11-25 University Of Utah Research Foundation Promoting angiogenesis with netrin1 polypeptides
JP5964538B2 (ja) 2005-02-03 2016-08-03 コーダ セラピューティクス， インコーポレイテッド 抗コネキシン化合物およびそれらの使用
WO2006091930A2 (en) 2005-02-24 2006-08-31 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
EP1978988A4 (en) 2006-01-13 2009-11-04 Univ New York State Res Found PEPTIDE-BASED REGULATION OF GAP-JUNCTIONS
US20100004168A1 (en) * 2006-06-30 2010-01-07 The Johns Hopkins University Use of Crystallin For The Modulation of Angiogenesis
US8247384B2 (en) * 2006-11-15 2012-08-21 Coda Therapeutics, Inc. Methods and compositions for wound healing
WO2008073466A2 (en) 2006-12-11 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Alpha b-crystallin as a therapy for inflammation
WO2009012224A2 (en) 2007-07-13 2009-01-22 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
AU2008295449A1 (en) * 2007-09-07 2009-03-12 Industrial Research Limited Agents with angiogenic and wound healing activity

Similar Documents

Publication Publication Date Title
JP2010538020A5 (cg-RX-API-DMAC7.html)
JP2010222367A5 (cg-RX-API-DMAC7.html)
CL2008002411A1 (es) Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.
JP2012041342A5 (cg-RX-API-DMAC7.html)
AR064944A1 (es) Molecula que comprende un fragmento de anticuerpo que enlaza especificamente el peptido a(beta) humano entre las posiciones de aminoacido 13 a 28, composicion que comprende dicha molecula y su uso para la preparacion de un medicamento
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
CL2008001125A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
JP2013155188A5 (cg-RX-API-DMAC7.html)
AR069135A1 (es) Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloide
WO2009154840A3 (en) Compositions and methods using stem cells in cutaneous wound healing
NO20084187L (no) Medikamenter og proteiner
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
CO6640218A2 (es) Heterociclilbencillporazoles sustituidos y uso de los mismos
JP2014530873A5 (cg-RX-API-DMAC7.html)
CO7310526A2 (es) Composición farmaceútica oral en forma de microesferas y proceso de elaboración
NZ583803A (en) Agents with angiogenic and wound healing activity
CU20160088A7 (es) Piperidinil-tetrahidroquinolinas sustituidas
PH12014501579A1 (en) Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
ATE283835T1 (de) Salze von asiatsäure und madecasssäure geeignet für die herstellung von pharmazeutischen und kosmetischen zusammensetzungen
UY28953A1 (es) Derivados heterocíclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas
EA201071138A1 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
JP2011012060A5 (cg-RX-API-DMAC7.html)